A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in pts <= 70 Yrs Old w/ Untreated Mantle Cell Lymphoma
Categories (click each to see list of all clinical trials associated with that category): Lymphoma/CLL (ONC)
Current Status: Open
Phase: II
Principal Investigator: Bociek, R Gregory
Contact Information:
Sarah Snook
sarah.snook@unmc.edu
Eligibility: https://www.clinicaltrials.gov/ct2/show/NCT04115631?cond=NCT04115631&draw=2&rank=1#eligibility
Summary